Shares of Immunome Inc.
blasted 212.6% higher toward new highs Thursday, to pace all of the premarket gainers trading on major U.S. exchanges, after biopharmaceutical company said it has isolated potent antibodies that are capable of neutralizing several SARS-CoV-2 variants, including the South African Variant (B.1.351) in pseudovirus testing. Trading volume was about 506,600 shares, compared with the full-day average of about 117,600 shares. The company has been working to develop a cocktail of antibodies (IMM-BCP-001) that can act as a treatment for COVID-19. “Our findings underscore the power of Immunome’s discovery engine to quickly identify antibodies that are broadly effective against SARS-CoV-2 and its variants,” said Chief Executive Purnanand Sarma. “We are encouraged by these results and plan to continue development efforts on these antibodies.” The stock, which went public on Oct. 2, 2020, has run up 129.6% year to date through Wednesday, while the iShares Nasdaq Biotechnology ETF
has advanced 10.6% and the S&P 500
has gained 4.7%.